Don't Jump to an SGLT2 Inhibitor for Heart Failure

November 2019

You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart failure...in patients withOUT diabetes.

Prior evidence suggests that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).

New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote